Can fractional laser resurfacing reduce skin cancer risk?

Modern platforms such as the Alma Pixel CO₂ laser highlight how contemporary ablative technologies are being explored beyond purely aesthetic indications.

Australia carries one of the highest burdens of non-melanoma skin cancer (NMSC) worldwide. Actinic keratoses (AKs), a common manifestation of cumulative ultraviolet (UV) exposure, are increasingly recognised not as isolated lesions but as markers of broader field cancerisation. While prevention strategies have traditionally focused on sun protection, surveillance and lesion-directed therapies, there is growing interest in whether procedural dermatology can favourably modify chronically sun-damaged skin at a biological level.

Fractional laser resurfacing, long established for skin rejuvenation and scar revision, has more recently been investigated for its potential role in reducing actinic burden and downstream cancer risk in high-risk populations. Emerging long-term data from randomised clinical trials and controlled clinical trials suggest this modality may offer benefits that extend beyond aesthetics.

Why chronically sun-damaged skin behaves differently

Ageing, UV-exposed skin exhibits a fundamentally altered response to ultraviolet radiation. Research, supported by five-year follow-up, has shown that geriatric dermal fibroblasts produce lower levels of insulin-like growth factor-1 (IGF-1), leading to impaired activation of the IGF-1 receptor on keratinocytes. This altered signalling results in an inappropriate proliferative response following UV exposure, increasing susceptibility to actinic keratoses and keratinocyte cancers.

Crucially, this dysfunction is driven by senescent fibroblasts within the dermis rather than surface changes alone. Treating individual lesions does not address this underlying pro-carcinogenic environment. Interventions capable of restoring healthier dermal-epidermal signalling may therefore offer broader, field-level benefit.

In the same studies, fractional wounding therapies have been shown to recruit non-senescent fibroblasts into treated skin, restoring IGF-1 expression and normalising the UV response. This biological rationale provides a compelling framework for investigating fractional laser resurfacing in actinic skin management.

Long-term clinical evidence

The most robust clinical data to date come from a prospective, randomised, single-blinded trial with extended follow-up, published in the Journal of the American Academy of Dermatology. In this study, 48 participants (>60 years, predominantly Fitzpatrick skin types I–II) with multiple actinic keratoses underwent a single session of fractionated laser resurfacing on one forearm, while the contralateral arm served as an untreated control.

This intra-patient design is a notable strength, effectively controlling for genetic, behavioural and environmental confounders. Participants were followed for up to 66 months (5.5 years).

From as early as three months post-treatment, the number of AKs on treated arms fell to less than half that of untreated arms. Importantly, this reduction was sustained at every follow-up time point throughout the entire study period. These findings extend earlier work from the same research group demonstrating significant AK reductions at six months and three years following a single ablative fractional laser treatment.

In addition to precancerous lesions, fewer non-melanoma skin cancers were observed on treated skin over long-term follow-up.

While the study was not primarily powered to assess cancer incidence, the directional reduction supports the concept that modifying the actinic field may influence disease progression, not simply lesion count.

How does this fit alongside existing field therapies?

Field-directed treatments such as topical 5-fluorouracil, imiquimod and photodynamic therapy remain cornerstones of actinic keratosis management. Fractional laser resurfacing differs in that it is a physical wounding modality rather than a pharmacological intervention.

Several studies have shown that ablative fractional lasers can enhance the efficacy of photodynamic therapy by improving photosensitiser penetration, reinforcing the idea that laser resurfacing may complement established field therapies.

For selected patients, fractional resurfacing may offer the added advantage of addressing both actinic damage and skin quality concerns within a single treatment paradigm.

What this evidence does, and does not, show

Current evidence supports the conclusion that fractional laser resurfacing can significantly reduce actinic keratoses in high-risk, chronically sun-damaged skin, with effects persisting for several years after a single treatment. Emerging data also suggest an association with fewer non-melanoma skin cancers in treated areas.

However, fractional laser resurfacing should not be considered a primary cancer prevention strategy. It does not replace sun protection, regular skin examinations or established medical therapies, and the
existing data are limited to older, fair-skinned populations with significant cumulative UV exposure.

Translating evidence into clinical practice

While the data discussed relate to fractional laser resurfacing as a modality rather than any specific device, they raise important questions about how contemporary ablative fractional CO₂ platforms may be applied in clinical practice.

Modern systems are designed to deliver controlled micro-ablative injury with predictable depth, density and thermal profiles, allowing clinicians to induce dermal remodelling while preserving surrounding tissue. Platforms such as the Alma Pixel CO₂ exemplify this evolution in fractional resurfacing technology, offering parameter flexibility that supports precise, clinician-directed treatment.

The evidence reviewed here should not be interpreted as device-specific proof or as a basis for cancer prevention claims. Rather, it highlights a growing body of research suggesting that fractional ablative resurfacing, when used judiciously as part of a comprehensive skin health strategy, may favourably modify chronically sun-damaged skin at a field level.

For more information, contact Alma Lasers Australia on on 02 8339 4791 or visit alma-lasers.com.au.